Poliovirus Vaccine (Inactivated)

Table of contents

  • Brand Names
  • Drug Combinations
  • Pharmacologic Category
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Dosage
  • Special Considerations

Brand Names


Austria: Polio Salk; Belgium: Imovax Polio; Bulgaria: Imovax Polio, Poliorix; Czech Republic: Imovax Polio, Veropol; Denmark: Poliovaccine; Estonia: Imovax Polio, Poliorix; Finland: Imovax Polio; France: Imovax Polio; Germany: Imovax Polio, IPV Merieux, IPV-Virelon; Greece: Imovax Polio; Ireland: Poliomyelitis Vaccine (Inactivated); Italy: Imovax Polio; Lithuania: Imovax Polio; Poland: Imovax Polio, Inaktywowana; Portugal: Imovax Polio, Poliovaccine; Romania: Imovax Polio, Opvero, Polio Sabin, Poliorix; Slovakia: Imovax Polio; Spain: Vacuna contra la Poliomielitis Inactivada: Sweden: Vaccin mot Polio, VeroPol.

North America

Canada: Imovax Polio, Inactivated Poliomyelitis Vaccine.

Latin America

Argentina: Imovax Polio, Opvero.

Drug combinations

Poliovirus (Type 1, 2, and 3), Diphtheria Toxoid, and Tetanus Toxoid

Poliovirus type 1 (Mahoney), Poliovirus type 2 (MEF 1), and Poliovirus type 3 (Saukett), Bordetella pertussis, Diphtheria Toxoid, Haemophilus influenza b Conjugate Vaccine, Hepatitis B surface Antigen (HbsAg), Pertactin, and Tetanus Toxoid


Pharmacologic Category

Serums, Toxoids, and Vaccines; Vaccines.(ATC-Code: J07BF).

Mechanism of action

Therapeutic use

Active immunization against poliomyelitis caused by poliovirus types 1, 2 and 3.

Pregnancy and lactiation implications

Animal reproduction studies not conducted. Vaccine may be administered to pregnant women at increased risk for infection and requiring immediate protection against polio. Excretion into breast milk unknown (use caution).

Unlabeled use


Hypersensitivity to any component of vaccine.

Warnings and precautions

Anaphylactoid and/or hypersensitivity might occur. Deferral of administration in moderate or severe acute illness should be considered (with or without fever). May be administered to patients with mild acute illness (with or without fever). Patients with prior clinical poliomyelitis or incomplete immunization with oral poliovirus vaccine may receive inactivated poliovirus vaccine. Immune response may be decreased in patients receiving immune globulin. Use with caution in severely immunocompromised patients. Patients with HIV infection, severe combined immunodeficiency, hypogammaglobulinemia, agammaglobulinemia, or altered immunity (due to corticosteroids, alkylating agents, antimetabolites or radiation) may receive inactivated poliovirus vaccine. Products may contain 2-phenoxyethanol, calf serum protein, formaldehyde, neomycin, polymyxin B, or streptomycin. Packaging may contain natural latex rubber.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart